BetterLife Pharma receives FINRA approval to resume trading on OTC Markets

BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) announced Wednesday that Glendale Securities Inc (the OTCQB sponsor) has received approval from the Financial Industry Regulatory Authority (FINRA) to quote and trade the company’s securities on the OTC Markets. BetterLife said it has satisfied the requirements of Rule 15c2-11 and will continue to use the trading symbol BETRF, enabling Glendale Securities to quote the company’s securities. BetterLife added that Form 211 clearance is crucial as it requires both the directors and principals of BetterLife and the company itself to pass stringent regulatory background checks and due diligence necessary to list in the US. READ: BetterLife Pharma and partner to manufacture its proprietary interferon alpha 2b to treat COVID-19 “This marks an important milestone as we begin to develop and execute our plans as a publicly-traded company in the U.S.,” said BetterLife CEO Dr Ahmad Doroudian in a statement. “We are at an enormously exciting moment in our evolution as a company. We are joining the fight against COVID-19 and will be sharing information on our upcoming human trials over the coming weeks with our shareholders and the market.’’ BetterLife is engaged in the development and commercialization of therapeutic pharmaceuticals as well as drug delivery platform technologies. Through its wholly-owned subsidiary, BLife Therapeutics Inc., BetterLife is refining and developing drug candidates from a broad set of complementary Interferon-based technologies, which have the potential to engage the immune system to fight virus infections, such as the coronavirus disease (COVID-19) and human papillomavirus (HPV), and/or to directly inhibit tumours to treat specific types of cancer. Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham